In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Joshua Carlos BernilUniversity of California San Francisco, Department of Laboratory Medicine, San Francisco, CA.ORCID 0009-0008-9261-8911 Princess RodriguezUniversity Vermont, Department of Molecular Genetics and Microbiology, Burlington, VT.ORCID 0009-0003-0790-9890 Etapong AyongabaUniversity of California San Francisco, Department of Laboratory Medicine, San Francisco, CA.
Elsa DrivetUniversity of Oslo, Institute of Clinical Medicine, Department of Immunology and KG Jebsen Center for B-cell Malignancies, Oslo, Norway.ORCID 0009-0006-3481-4071 Amrita PalariaUniversity of California San Francisco, Department of Laboratory Medicine, San Francisco, CA.ORCID 0000-0003-2107-401X Mariam DajaniUniversity of California San Francisco, Department of Laboratory Medicine, San Francisco, CA.
Els VerhoeyenUniversité Côte d'Azur, INSERM, C3M, 06204 Nice, France.
Gary S SteinUniversity Vermont, Department of Biochemistry, Burlington, VT.
Hilde SchjervenUniversity of California San Francisco, Department of Laboratory Medicine, San Francisco, CA.ORCID 0000-0001-9287-3375 Funding
Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Julie Dragon · 2012 to 2026
$58.4MUnderstanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Robert A Koza · 2017 to 2026
$51.6MResearch BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8MUnderstanding Ikaros molecular functions for targeted therapies of pre-B ALLR01CA230618 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRIETZE, SETH E, SCHJERVEN, HILDE · 2018 to 2022
$1.8MMechanism of Ikaros Tumor Suppression in progenitor B cell leukemiaR21CA209229 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRIETZE, SETH E, SCHJERVEN, HILDE · 2016 to 2017
$420kCytek Aurora 5-Laser Spectral Flow CytometerS10OD026940 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SIMOES MARTINS BISPO, CLAUDIA · 2019 to 2019
$341kNCI NIH HHS R01 CA230618NCI NIH HHS R21 CA209229NIDDK NIH HHS P30 DK063720NIGMS NIH HHS P20 GM103449NIGMS NIH HHS U54 GM115516NIH HHS S10 OD026940
6 · The paper itselfAbstract
B-cell acute lymphoblastic leukemia (B-ALL) is driven by transcriptional dysregulation that impairs B-cell differentiation and sustains leukemic growth. A defining feature of high-risk B-ALL is mutations in
Identifiers
PMID41509392
PMCPMC12776271
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390